Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minetta C Liu

Showing results (131-140 of 159) with videos related to

Pageof 16
Sort By:
Breast Cancer Research and Treatment|January 23, 2023
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT studyMark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, et al.
Nature Medicine|June 8, 2026
Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trialHideaki Bando, Jun Watanabe, Yusuke Takahashi, et al.
JCO Precision Oncology|May 1, 2024
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast CancerJacqueline A Shaw, Karen Page, Evie Wren, et al.
Nature Medicine|September 16, 2024
ctDNA-based molecular residual disease and survival in resectable colorectal cancerYoshiaki Nakamura, Jun Watanabe, Naoya Akazawa, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
Cancers|February 27, 2026
Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant TherapySakti Chakrabarti, Stacey A Cohen, Antony Tin, et al.
JAMA Oncology|June 20, 2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled TrialMichael Cecchini, Ronald R Salem, Marie Robert, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Breast Cancer Research and Treatment|May 8, 2020
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015Peter H O'Donnell, Vassily Trubetskoy, Ashley Nurhussein-Patterson, et al.
Frontiers in Oncology|October 5, 2023
ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapyEmily S Lebow, Narek Shaverdian, Jordan E Eichholz, et al.
Pageof 16

Showing results (131-140 of 159) with videos related to

Sort By:
Pageof 16
Breast Cancer Research and Treatment|January 23, 2023
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT studyMark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, et al.
Nature Medicine|June 8, 2026
Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trialHideaki Bando, Jun Watanabe, Yusuke Takahashi, et al.
JCO Precision Oncology|May 1, 2024
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast CancerJacqueline A Shaw, Karen Page, Evie Wren, et al.
Nature Medicine|September 16, 2024
ctDNA-based molecular residual disease and survival in resectable colorectal cancerYoshiaki Nakamura, Jun Watanabe, Naoya Akazawa, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
Cancers|February 27, 2026
Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant TherapySakti Chakrabarti, Stacey A Cohen, Antony Tin, et al.
JAMA Oncology|June 20, 2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled TrialMichael Cecchini, Ronald R Salem, Marie Robert, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Breast Cancer Research and Treatment|May 8, 2020
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015Peter H O'Donnell, Vassily Trubetskoy, Ashley Nurhussein-Patterson, et al.
Frontiers in Oncology|October 5, 2023
ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapyEmily S Lebow, Narek Shaverdian, Jordan E Eichholz, et al.
Pageof 16